Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04817267 · ClinicalTrials.gov registry record · NA
Pilot Study of reSET-O to Treatment-as-usual in Acute Care Settings
A NA study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT04817267: Clinical Trial NA study, sponsored by Johns Hopkins University.
NCT04817267 is a NA study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 8 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04817267, a NA study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
This randomized controlled pilot study will evaluate feasibility, acceptability, and potential efficacy of an app, reSET-O, for patients being started on buprenorphine in acute care settings.
Primary Outcome
Percentage of approached patients who are eligible for and interested in participation will be used to assess feasibility.
Interventions
- DEVICE reSET-O app
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-03-11 |
| Est. Completion | 2024-05-01 |
| Phase | NA |
Why NCT04817267 stopped before completion
NCT04817267 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which reSET-O app is the first listed.
NCT04817267 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04817267 about?
NCT04817267 is a clinical study titled "Pilot Study of reSET-O to Treatment-as-usual in Acute Care Settings". This randomized controlled pilot study will evaluate feasibility, acceptability, and potential efficacy of an app, reSET-O, for patients being started on buprenorphine in acute care settings.
What is the current status of trial NCT04817267?
This trial is currently terminated. It is a NA study. The enrollment target is 8 participants. The study started on 2022-03-11. Estimated completion is 2024-05-01.
What interventions are being tested in trial NCT04817267?
The interventions under investigation include: reSET-O app (DEVICE).
Who is sponsoring clinical trial NCT04817267?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04817267's enrollment target sits among peer trials
8 1976th of 2000 higher than 19 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI